Palvella Therapeutics
PVLA
130.59
+2.59
+2.02%
Palvella Therapeutics
US · PVLA
#2822 by market cap
Listed 1970
130.59
+2.59
+2.02%
Live - 5344 symbols - heartbeat 535s ago
· 2026-10-08 04:00
Pre-market
131.00
+0.31%
After-hours
130.70
+0.08%
Overnight
130.05
-0.41%
- Market cap
- 1.88B
- P/E (TTM)i
- -26.93
- P/Bi
- 8.68
- EPSi
- -3.71
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on PVLA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.4 percentage points.
Institutional ownership
- Held by institutions
- 107.89% -1.36pp
- Institutions
- 239 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund62.89%
Hedge Fund19.98%
VC/PE Fund14.92%
Individual/Insider8.01%
Private Company4.26%
Public Company3.46%
Sovereign Wealth Fund1.85%
Government Pension Fund0.26%
Insurance Company0.22%
Top holders as of 2026-06-30
Montanova Capital, LLC
7.88% · 1.14M sh
Jennison Associates LLC
6.67% · 960.62K sh
BlackRock
6.37% · 918.36K sh
Frazier Life Sciences Management, LP
6.12% · 882.40K sh
Wesley Kaupinen
5.73% · 825.82K sh
First Light Asset Management, LLC
5.36% · 771.90K sh
BVF Partners L.P.
4.67% · 672.79K sh
State Street Global Advisors
4.53% · 653.17K sh
T. Rowe Price Group, Inc.
4.43% · 638.87K sh
Vanguard Capital Management, LLC
4.08% · 587.79K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Wesley Kaupinen | Chief Executive Officer | 5.73% |
| George Jenkins | Chairperson | 1.11% |
| Todd Davis | Director | 0.78% |
| Elaine Heron | Director | 0.37% |
| Matthew Korenberg | Chief Financial Officer | 0.01% |
| Christopher Kiritsy | Independent Director | 0.00% |
| BVF Partners L.P. | -- | -- |
| Tadd Wessel | Director | -- |
| John Doux | Director | -- |
| Matthew Pauls | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–153.24 |
| 2026-09-14 | George Jenkins | Chairperson | Automatic Disposition | -27,500 | $149.38–153.10 |
| 2026-09-10 | George Jenkins | Chairperson | Intent to Sell (Form 144) | -27,500 | $150.39 |
| 2026-09-01 | Christopher Kiritsy | Independent Director | Derivative Exercise and Sale | -313 | $127.20–157.00 |
| 2026-08-18 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–156.77 |
| 2026-07-14 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–150.25 |
| 2026-06-28 | Matthew Pauls | Director | Other Derivative Acquisition | +6,000 | $154.84 |
| 2026-06-16 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–112.23 |
| 2026-06-11 | Matthew Korenberg | Chief Financial Officer | Derivative Exercise and Retained | +1,000 | $13.60 |
| 2026-06-09 | George Jenkins | Chairperson | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Elaine Heron | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Todd Davis | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Christopher Kiritsy | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Tadd Wessel | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | John Doux | Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-05-19 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–111.90 |
| 2026-04-14 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–130.33 |
| 2026-04-12 | John Doux | Director | Other Derivative Acquisition | +6,000 | $129.00 |
| 2026-04-12 | John Doux | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-29 | George Jenkins | Chairperson | Open Market Acquisition | +445 | $112.30 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.